HEALTHEURACTIV
Commission defends one-year SPC extension under Biotech Act despite criticism over costs
The Commission is defending a one-year extension of SPC under the Biotech Act, which faces criticism due to costs and has caused division among lawmakers and industry stakeholders.
Mentioned
Related Signal
Adjacent reporting
- Spy-law extension at risk after Senate votes against launching debate
- Congress passes short-term FISA extension
- Push for 3-week FISA 702 extension draws swift pushback from Senate Democrats
- UN Security Council extends Afghan mission for one year
- Trump signs stopgap FISA extension after Senate blocks long-term renewal